Welcome to our dedicated page for Therapeutic Solutions Intl news (Ticker: TSOI), a resource for investors and traders seeking the latest updates and insights on Therapeutic Solutions Intl stock.
Therapeutic Solutions Intl Inc (TSOI) delivers cutting-edge therapeutic innovations through focused biomedical research and strategic industry partnerships. This news hub provides investors and healthcare professionals with essential updates on clinical developments, regulatory milestones, and corporate initiatives.
Access real-time information about TSOI's progress in developing novel therapies, including clinical trial results, FDA submissions, and research collaborations. Our curated news collection simplifies tracking of the company's advancements in biotechnology and pharmaceutical development.
Key updates include progress reports on therapeutic pipelines, intellectual property developments, and financial performance announcements. All content undergoes strict verification to ensure alignment with regulatory standards and factual accuracy.
Bookmark this page for streamlined access to TSOI's latest scientific achievements and corporate news. Regularly updated information helps stakeholders make informed decisions based on verified company developments.
Therapeutic Solutions International (TSOI) has announced its intention to voluntarily delist from public markets and 'go dark.' The decision, approved by the Board of Directors and majority shareholders on April 22, 2025, comes after the company's market cap dropped from $400 million to below $10 million over three years, with shares trading at $0.0001.
The company will initiate the delisting process through Form 8-K filing, followed by Form 25 and Form 15 submissions after mandatory 10-day waiting periods. CEO Timothy G Dixon describes this move as a strategic pause rather than surrender, aimed at escaping what he terms 'toxic cycle of dilution and manipulation.'
During this period, TSOI will focus on its subsidiaries: Breathe Biologics, Campbell Neurosciences, and Res Nova Bio. The company plans to explore potential sales or partnerships of these subsidiaries, with a commitment to return a portion of any proceeds to shareholders through dividends or stock buybacks.
Therapeutic Solutions International (TSOI) has received a Notice of Allowance from the US Patent and Trademark Office for a patent on using T regulatory cells to enhance the efficacy of mesenchymal stem cells in treating lung inflammation. This patent covers a method to reduce lung inflammation through the administration of T regulatory cells combined with mesenchymal stem cells. The company is developing treatments for COVID-19, ARDS, COPD, and pulmonary fibrosis, all involving lung inflammation. The patent is expected to increase TSOI's value, with comparisons to successful deals in the sector, such as Regeneron-Sonoma and Quell-AstraZeneca.
Therapeutic Solutions International's pre-spin-off company, Campbell Neurosciences, appoints Raymond Oliver as Chairman of the Board to facilitate its entry into the capital markets. The company plans to distribute up to 10,000,000 shares to existing shareholders in a loyalty dividend. Campbell Neurosciences is focused on developing innovative technologies for the treatment of psychiatric diseases and suicidal propensities.
